MPB
巨生生醫股份有限公司
MPB is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is MPB-2043 (Phase 1; recruiting, Head and Neck Squamous Cell Carcinoma; Lymph Node Metastasis), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| MPB-2043 | — | Phase 1; recruiting | Head and Neck Squamous Cell Carcinoma; Lymph Node Metastasis | Taiwan | 2025-05-08 | Trial registry |
| MPB-1514 | — | Phase 2; terminated | Iron Deficiency Anemia | United States | 2021-10-28 | Trial registry |
| MPB-1734 | — | — | — | — | — | Company disclosure |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.